These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 9147520)

  • 1. Modification of mutant K-ras gene expression in non-small cell lung cancer (NSCLC).
    Roth JA
    Hum Gene Ther; 1996 May; 7(7):875-89. PubMed ID: 9147520
    [No Abstract]   [Full Text] [Related]  

  • 2. Modification of tumor suppressor gene expression in non-small cell lung cancer (NSCLC) with a retroviral vector expressing wildtype (normal) p53.
    Roth JA
    Hum Gene Ther; 1996 May; 7(7):861-74. PubMed ID: 8860838
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-tumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants in nude mice.
    Zhang YA; Nemunaitis J; Scanlon KJ; Tong AW
    Gene Ther; 2000 Dec; 7(23):2041-50. PubMed ID: 11175317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular approaches to prevention and therapy of aerodigestive tract cancers.
    Roth JA; Mukhopadhyay T; Tainsky MA; Fang K; Casson AG; Schneider PM
    J Natl Cancer Inst Monogr; 1992; (13):15-21. PubMed ID: 1327031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. K-ras mutations in non-small-cell lung carcinoma: a review.
    Aviel-Ronen S; Blackhall FH; Shepherd FA; Tsao MS
    Clin Lung Cancer; 2006 Jul; 8(1):30-8. PubMed ID: 16870043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms.
    Sutterlüty H; Mayer CE; Setinek U; Attems J; Ovtcharov S; Mikula M; Mikulits W; Micksche M; Berger W
    Mol Cancer Res; 2007 May; 5(5):509-20. PubMed ID: 17510316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of tumor inhibition and apoptosis by a candidate tumor suppressor gene DRR1 on 3p21.1.
    Liu Q; Zhao XY; Bai RZ; Liang SF; Nie CL; Yuan Z; Wang CT; Wu Y; Chen LJ; Wei YQ
    Oncol Rep; 2009 Nov; 22(5):1069-75. PubMed ID: 19787223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment based on biological characteristics of lung cancer: biological differences between small cell and non-small cell lung cancer and gene therapy].
    Tanio Y
    Gan To Kagaku Ryoho; 1997 Oct; 24 Suppl 3():337-44. PubMed ID: 9369905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel molecular staging protocol for non-small cell lung cancer.
    Miyake M; Adachi M; Huang C; Higashiyama M; Kodama K; Taki T
    Oncogene; 1999 Apr; 18(14):2397-404. PubMed ID: 10327061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative evaluation of retroviral gene transduction efficiency in human lung cancer cells.
    Rousculp MD; Goldsmith KT; Garver RI
    Hum Gene Ther; 1992 Oct; 3(5):471-7. PubMed ID: 1329992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of a ribozyme-adenoviral vector against K-ras mutant human lung cancer cells.
    Zhang YA; Nemunaitis J; Tong AW
    Mol Biotechnol; 2000 May; 15(1):39-49. PubMed ID: 10911621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. K-ras activation in non-small cell lung cancer in the dog.
    Kraegel SA; Gumerlock PH; Dungworth DL; Oreffo VI; Madewell BR
    Cancer Res; 1992 Sep; 52(17):4724-7. PubMed ID: 1324792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 tumor suppressor gene therapy for cancer.
    Roth JA; Swisher SG; Meyn RE
    Oncology (Williston Park); 1999 Oct; 13(10 Suppl 5):148-54. PubMed ID: 10550840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modification of tumor suppressor gene expression and induction of apoptosis in non-small cell lung cancer (NSCLC) with an adenovirus vector expressing wildtype p53 and cisplatin.
    Roth JA
    Hum Gene Ther; 1996 May; 7(8):1013-30. PubMed ID: 8727511
    [No Abstract]   [Full Text] [Related]  

  • 15. Down-regulation of microRNA-181b is a potential prognostic marker of non-small cell lung cancer.
    Yang J; Liu H; Wang H; Sun Y
    Pathol Res Pract; 2013 Aug; 209(8):490-4. PubMed ID: 23827213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of RalA signaling pathway in treatment of non-small cell lung cancer.
    Male H; Patel V; Jacob MA; Borrego-Diaz E; Wang K; Young DA; Wise AL; Huang C; Van Veldhuizen P; O'Brien-Ladner A; Williamson SK; Taylor SA; Tawfik O; Esfandyari T; Farassati F
    Lung Cancer; 2012 Aug; 77(2):252-9. PubMed ID: 22498113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A modified mutagenic PCR-RFLP method for K-ras codon 12 and 13 mutations detection in NSCLC patients.
    Hatzaki A; Razi E; Anagnostopoulou K; Iliadis K; Kodaxis A; Papaioannou D; Labropoulos S; Vasilaki M; Kosmidis P; Saetta A; Mihalatos M; Nasioulas G
    Mol Cell Probes; 2001 Oct; 15(5):243-7. PubMed ID: 11735295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of Bcl-2 and mutations in p53 and K-ras in resected human non-small cell lung cancers.
    Kitagawa Y; Wong F; Lo P; Elliott M; Verburgt LM; Hogg JC; Daya M
    Am J Respir Cell Mol Biol; 1996 Jul; 15(1):45-54. PubMed ID: 8679221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ras gene family in human non-small-cell lung cancer.
    Slebos RJ; Rodenhuis S
    J Natl Cancer Inst Monogr; 1992; (13):23-9. PubMed ID: 1327034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 Gene therapy for lung cancer.
    Swisher SG; Roth JA
    Curr Oncol Rep; 2002 Jul; 4(4):334-40. PubMed ID: 12044243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.